ArticleCureus2025
Comparative Effectiveness and Safety of Amlodipine, Telmisartan, and Chlorthalidone in Newly Diagnosed Hypertensive Indian Adults.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of amlodipine and telmisartan on bone metabolism markers in newly diagnosed hypertensive patients.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAmlodipine, telmisartan, and chlorthalidone are the most prescribed antihypertensive drugs in the Indian population. In this study, we compared the effectiveness and safety of these drugs in newly diagnosed hypertensive adults.
methodsThis was an open-label, prospective observational study in which we enrolled 99 newly diagnosed stage I hypertensive patients who were prescribed amlodipine (33 patients), telmisartan (33 patients), or chlorthalidone (33 patients) monotherapy. The primary endpoint was to compare the changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at days 15, 30, 45, 60, and 90 from baseline among the three treatment groups. Secondary endpoints include incidence of adverse drug reactions (ADRs); changes in body weight, blood glucose, and lipid profile; and kidney function test on day 90 compared to baseline.
resultsAll three groups showed a significant decrease in SBP and DBP on follow-up visits in comparison to baseline (p < 0.01), and the target BP was achieved by day 30. The incidence of ADRs was found to be lower in the telmisartan group (three) compared to the amlodipine group (five) and the chlorthalidone group (nine). The chlorthalidone group showed a significant increase in blood glucose and lipid levels (p < 0.05), whereas the telmisartan group showed a significant decrease in blood glucose and lipid levels (p < 0.05).
conclusionTelmisartan is more effective and safer as initial monotherapy followed by amlodipine than chlorthalidone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.